Key result
Fluorodeoxyglucose PET imaging effectively identified metastatic disease to the heart in two cases, revealing unsuspected myocardial metastases and characterizing an intraatrial mass.
Why the study?
Can FDG PET imaging effectively identify cardiac metastases despite physiological myocardial uptake?
Case Report (n=2)
Can FDG PET imaging effectively identify cardiac metastases despite physiological myocardial uptake?
Answers are grounded in this paper and cite their sources.
FDG PET imaging can be a useful tool for identifying and characterizing cardiac metastases, despite the potential for physiological myocardial uptake to obscure findings.
Physiological fluorodeoxyglucose (FDG) uptake can obscure underlying disease or can even falsely suggest disease in patients undergoing whole-body positron emission tomography (PET) scanning for disease staging. Myocardial uptake in particular can present a problem because of its variability in fasting patients. Nonetheless, we present 2 cases in which FDG PET imaging was effective in identifying metastatic disease to the heart. In 1 case, an FDG PET scan revealed previously unsuspected myocardial metastases. In another case, FDG PET was useful in characterizing an intraatrial mass seen on anatomic imaging as a metabolically active lesion.
No takes yet. Share an insight, caveat, or question.
Nguyen et al. (2003) conducted a case report in Cardiac metastases (n=2). Fluorodeoxyglucose (FDG) Positron Emission Tomography (PET) was evaluated on Identification of metastatic disease to the heart. Fluorodeoxyglucose PET imaging effectively identified metastatic disease to the heart in two cases, revealing unsuspected myocardial metastases and characterizing an intraatrial mass.
Synapse has enriched 10 related papers. Consider them for comparative context: